A2 Biotherapeutics, Inc. | $80,000,000 | (Jan 10, 2025)
Prudentia Sciences | $7,000,000 | (Jan 10, 2025)
RLTYco | $20,000,000 | (Jan 10, 2025)
RyboDyn Inc.
United States
- San Diego, California
- 10/01/2025
- Pre-Seed
- $4,000,000
RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.
- Industry Biotechnology Research
- Website https://www.rybodyn.com/
- LinkedIn https://www.linkedin.com/company/rybodyn/
Related People
Imad Ajjawi, PhD, MBACo Founder
United States -
San Diego, California
Biotechnology entrepreneur passionate about revolutionizing the biotech industry. Founded Denovium, an AI biotech company for protein discovery and design. Acquired by Absci. IPO less than a year later at a $1.5B pre-money valuation. Secured >$100M funds via strategic partnerships, M&A and VCs. Authored >25 patents and peer-reviewed manuscripts (see Google Scholar). Featured in WIRED, Forbes, Bloomberg, NPR, and other media outlets.
Air | $35,000,000 | (Jan 10, 2025)
Biosphere | $8,800,000 | (Jan 10, 2025)
Abstract(US) | $4,800,000 | (Jan 10, 2025)
PrettyDamnQuick | $25,000,000 | (Jan 10, 2025)
Oxford Cancer Analytics | $11,000,000 | (Jan 10, 2025)
UNLISTED | $2,250,000 | (Jan 9, 2025)
Zeto / Rapid Full-Montage EEG | $31,000,000 | (Jan 9, 2025)
Red Rover Health, Inc. | $4,000,000 | (Jan 9, 2025)